文献速递甲状腺核医学核素与放射性配体治疗

放射性碘治疗对甲状腺乳头状癌和滤泡状癌患者长期相对生存的影响:基于SEER数据库涵盖组织学亚型与复发风险分层的分析

Impact of Radioactive Iodine Treatment on Long-Term Relative Survival in Patients with Papillary and Follicular Thyroid Cancer: A SEER-Based Study Covering Histologic Subtypes and Recurrence Risk Categories.
PubMed 文献 · J Nucl Med · 2025-03-13

该回顾性研究基于SEER数据库2000至2020年101,087例分化型甲状腺癌患者,比较接受与未接受放射性碘治疗后的长期相对生存。结果显示多数亚组中放射性碘治疗组相对生存率更高或趋于更高,高危组获益可达30.9%,且无任何亚组相对生存受损。

要点

  • 多数分化型甲状腺癌亚组中,放射性碘治疗组相对生存率高于或趋于高于未治疗组。
  • 高危分化型甲状腺癌中观察到相对生存获益最高达30.9%(P<0.05)。
  • 微小浸润型滤泡状癌低危组10年相对生存率趋于高2.0%(P=0.055)。

核心结论

  • 分化型甲状腺癌患者中,按组织学亚型分层,低危、中危和高危亚组接受放射性碘治疗者较未接受者存在相对生存获益。
  • 低危微小浸润型滤泡状癌也观察到生存率更高的明显趋势。
  • 乳头状癌中,存在淋巴结受累、较大肿瘤尺寸或远处转移时存在生存获益。

研究设计与样本

  • 回顾性比较接受与未接受放射性碘治疗的分化型甲状腺癌队列的长期相对生存。
  • 从SEER数据库识别2000年至2020年间101,087例分化型甲状腺癌患者。
  • 按组织学分为经典型乳头状癌、侵袭性变异型乳头状癌、滤泡状癌和微小浸润型滤泡状癌。
  • 各队列按极低危、低危、中危和高危分层,计算各亚组相对生存。
  • 统计采用专门用于比较相对生存的z检验,检验放射性碘治疗的长期效应(3年、5年和10年)。

主要发现

  • 多数接受放射性碘治疗亚组的相对生存率高于或趋于高于未接受放射性碘治疗亚组。
  • 低危微小浸润型滤泡状癌中,放射性碘治疗组10年相对生存率趋于高2.0%(P=0.055)。
  • 经典型乳头状癌中较大肿瘤尺寸或淋巴结受累时,放射性碘治疗亚组10年相对生存获益为1.3%–2.0%(P=0.045)。
  • 高危分化型甲状腺癌中观察到相对生存获益最高达30.9%(P<0.05)。
  • 任何放射性碘治疗亚组的相对生存均未受到负面影响。

关键数值与推荐

  • 美国甲状腺协会和欧洲甲状腺协会一般推荐术后放射性碘治疗仅用于高危患者。
  • 中危患者中,放射性碘治疗仅作为应考虑的选项被推荐。
  • 低危患者中,不常规推荐放射性碘治疗。
  • 其他国家如德国更倾向于使用放射性碘。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For patients with differentiated thyroid cancer (DTC), that is, papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC), the American Thyroid Association and European Thyroid Association generally recommend radioactive iodine (RAI) therapy after surgery only for high-risk patients. For intermediate-risk patients, RAI therapy is recommended only as a should-be-considered option. For low-risk patients, RAI therapy is not routinely recommended. Other countries, such as Germany, are more in favor of using RAI. Thus, RAI therapy remains a matter of controversial debate, because prospective long-term data on survival are scarce. Methods: We retrospectively compared long-term relative survival in DTC cohorts treated with and without RAI. From the Surveillance, Epidemiology, and End Results Program database, 101,087 patients harboring DTC were identified between 2000 and 2020. Patient cohorts were subdivided based on histology (classical PTC, aggressive variants of PTC, FTC, and minimally invasive FTC). These cohorts were stratified into the following categories: very low risk, low risk, intermediate risk, and high risk. Relative survival was determined for each subgroup. Statistics included a z-test specifically developed for comparison of relative survival, testing the long-term effect of RAI therapy (3, 5, and 10 y). Results: The relative survival rate is higher or tends to be higher in most subgroups undergoing RAI therapy than in subgroups not undergoing RAI therapy. Even for low-risk minimally invasive FTC, the 10-y relative survival rate tends to be higher by 2.0% (P = 0.055). For larger tumor size or lymph node involvement in classical PTC, a 10-y relative survival benefit of 1.3%-2.0% (P = 0.045) in the RAI subgroup prevails. In high-risk DTC, benefits in relative survival of up to 30.9% (P < 0.05) were observed. Relative survival is not negatively affected in any RAI subgroup. Conclusion: In patients with DTC, depending on histology subtype, a benefit in relative survival prevails in low-, intermediate-, and high-risk subgroups that underwent RAI therapy compared with patients who did not undergo RAI therapy. Even in low-risk minimally invasive FTC, a clear trend toward higher survival rates is observed. For PTC, a survival benefit prevails in the presence of lymph node involvement, larger tumor size, or distant metastasis.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Weis H, Weindler J, Schmidt K, et al. Impact of Radioactive Iodine Treatment on Long-Term Relative Survival in Patients with Papillary and Follicular Thyroid Cancer: A SEER-Based Study Covering Histologic Subtypes and Recurrence Risk Categories. J Nucl Med. 2025. PMID: 40081954. doi:10.2967/jnumed.124.269091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。